Notice: Get a jump on 2015 — Pay your 2015 ASA membership dues now!

>

MEETINGS / EVENTS

RSS

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

June 26 - 28 2015, 12:00 AM - 12:00 AM

Annual Perioperative Surgical Home Summit

>

FDA MEDWATCH ALERTS

December 18, 2014

0.9 Percent Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container by Baxter: Recall - Particulate Matter

Summary:

FDA MedWatch Recall - Particulate Matter

November 21, 2014

FDA MedWatch - Respironics California, Esprit V1000 and V200 Ventilators: Class I Recall - Power Failure May Occur

Summary:

FDA MedWatch Respironics California Esprit V1000 and V200 Ventilators Class I Recall

November 21, 2014

FDA MedWatch - Highly Concentrated Potassium Chloride Injection, 10 mEq per 100 mL by Baxter: Recall - Mislabeled

Summary:

Highly Concentrated Potassium Chloride Injection 10 mEq per 100 mL by Baxter Recall Mislabeled

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

ASA Responds to Federal Trade Commission's Proposed Statement on ACO Antitrust Enforcement

Tuesday, May 31, 2011

In conjunction with the release of the Centers for Medicare and Medicaid Services (CMS) proposed rule on Accountable Care Organizations (ACOs), the Federal Trade Commission (FTC) released a proposed statement of antitrust enforcement policy regarding ACOs participating in the Medicare Shared Savings Program. The ASA recently submitted a letter to the FTC in response to the proposed statement.  Next week, the ASA will submit comprehensive comments to CMS on the proposed ACO rule.

In the letter to the FTC, the ASA states it is in general agreement with comments made by the American Medical Association. The ASA letter goes on to detail how the proposed statement would impact anesthesiologists specifically.   

ASA concludes the letter by stating: “To ensure the success of the Shared Savings Program, it is critical for CMS and the FTC/DOJ to develop a Shared Savings Program and associated antitrust clearance process that enables the majority of physicians to develop, lead and actively participate in ACOs.  While ASA supports the application of the rule of reason to ACOs, we have serious reservations about the market power implications and their impact on anesthesiologists.“

Click here to read the letter submitted by ASA.

Click here to read the FTC proposed statement.

Click here for the latest information on the work ASA is doing regarding ACOs.

 

 

« Back to Washington Alerts